WASHINGTON — With a slew of congressional hearings that have proved to be more about posturing than policy, presidential pronouncements about murderous drug companies, and rumors of executive orders that never materialize, it’s easy to grow disillusioned by the debate over drug prices in Washington.

But as the Federal Trade Commission prepares to host federal officials and other experts to discuss the issue Wednesday, there’s an unusual degree of excitement about the possibility that the agency — which can function as part law office, part think tank — could effect meaningful change to rein in prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The George W Bush adminstration pushed for and got a provision that forbids Medicare bargaining on cost of drugs. Three years ago the Department of Veterans Affairs, VA, got Lipitor for less than $2.00 a dose. Medicare paid more than $4.00. That’s more than twice the price. Duh!, government of mine.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy